The physical, cognitive, and organizational ergonomics in robotic surgery: A systematic review of experimental studies.

SurgeonJul 15, 2026 (epub)
Clinical ResearchGeneral SurgeryCardiothoracic SurgeryOrthopedic Surgery

Uresha Lakshani, Ghulam H Abbas, Alba Zevallos et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the ergonomic benefits of robotic-assisted surgery (RAS) compared to traditional laparoscopic surgery (TLS) across 17 studies, including 14 randomized controlled trials. The review found that RAS significantly enhances physical ergonomics by reducing physical demands and discomfort, while improving dexterity and ease of use, and lowers the risk of work-related musculoskeletal disorders (MSDs) compared to TLS.

Key findings

  • RAS significantly reduces physical demands and discomfort for surgeons compared to TLS.
  • RAS improves dexterity and ease of use in surgical procedures.
  • The risk of work-related musculoskeletal disorders (MSDs) is lower with RAS than with TLS.

Why it matters

Understanding the ergonomic advantages of robotic-assisted surgery can help clinicians appreciate its potential to enhance surgeon well-being and performance, ultimately impacting patient outcomes.

Source

PubMed · PMID 42457608

Published in Surgeon. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in General Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.